Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trialChuanjie Wu, Lijun Wang, Yajun Lian et al.|Cephalalgia|2012Cited by 217
LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cellsYuan Chen, Nanchang Xie, Yajun Lian et al.|NeuroToxicology|2017Cited by 103
Therapeutic effect of Botulinum toxin-A in 88 patients with Trigeminal Neuralgia with 14-month follow-upShuang Li, Yi Zhang, Caihong He et al.|The Journal of Headache and Pain|2014Cited by 61
Central antinociceptive activity of peripherally applied botulinum toxin type A in lab rat model of trigeminal neuralgiaChuanjie Wu, Haifeng Zhang, Nanchang Xie et al.|SpringerPlus|2016Cited by 49
Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystoniaChuanjie Wu, Chen Chen, Fang Xue et al.|SpringerPlus|2016Cited by 32